Latest news about Anuh Pharma
Anuh Pharma
75.53
-1.33(-1.73%)
Company Performance:
View Company Insights1D-1.73%
1M-6.98%
6M-5.55%
1Y-30.55%
5Y-32.22%
More news about Anuh Pharma
08Apr 26
Anuh Pharma Limited Submits SEBI Compliance Certificate for Q4FY26
Anuh Pharma Limited filed its Q4FY26 certificate under SEBI Regulation 74(5) on 07th April, 2026, confirming no dematerialisation requests were received during January-March 2026. The certificate was provided by RTA Bigshare Services Private Limited and submitted to BSE and NSE by Company Secretary Manan Vadhan, demonstrating the company's regulatory compliance.
09Mar 26
Anuh Pharma: Company Reports Maharashtra Facility Passed EDQM Audit Successfully
Anuh Pharma Limited has successfully completed a regulatory audit by the European Directorate for Quality of Medicines & HealthCare (EDQM) at its Maharashtra manufacturing facilities. The audit covered three units at Tarapur and found them compliant with stringent international quality standards, validating the company's manufacturing processes and quality control systems.
08Feb 26
Anuh Pharma Limited Publishes Q3FY26 Unaudited Financial Results Under Regulation 47
Anuh Pharma Limited published Q3FY26 unaudited financial results showing revenue of ₹19,717.81 lakhs and net profit of ₹1,345.10 lakhs. The company demonstrated strong growth with EBITDA margin of 10.60% and adjusted EBITDA margin of 12.18%. Nine months revenue reached ₹56,954.02 lakhs with EPS of ₹2.93, reflecting robust operational performance.
21Jan 26
Anuh Pharma Limited Receives Income Tax Assessment Order with ₹78.29 Lakh Tax Demand for AY 2020-21
Anuh Pharma Limited disclosed receiving an Income Tax Assessment Order for AY 2020-21 with a tax demand of ₹78,28,793 including interest, arising from disallowed deductions. The company received the order on January 20, 2026, and plans to file an appeal before Higher Appellate Forums. Management believes it has adequate grounds to contest the order and states there is no impact on financial operations or other company activities.
17Nov 25
Anuh Pharma Reports 21% Revenue Growth in H1 FY2026, Projects 15-16% Annual Growth Rate
Anuh Pharma's revenue increased by 21.14% to Rs 376.73 crores in H1 FY2026. EBITDA remained nearly flat at Rs 75.20 crores. The company expanded manufacturing capacity to 2400 MTPA across 9 API blocks and 2 intermediate blocks. Anuh Pharma expects margin recovery in H2 FY2026 due to operational efficiencies and higher capacity utilization. The company focuses on market expansion, new product addition, and exploring inorganic growth opportunities. A robust product pipeline includes drugs for various conditions. Anuh Pharma projects an annual growth rate of 15-16%.
07Nov 25
Anuh Pharma Reports Q2 Revenue Growth Amid Profit Decline
Anuh Pharma's Q2 results show revenue growth of 12.7% to ₹1.86 billion, but net profit declined by 49.3% to ₹76.00 million. EBITDA fell 29.6% to ₹119.00 million, with margins shrinking by 378 bps. Half-year revenue increased 22.5% to ₹3,723.62 crore, while net profit decreased 35.2% to ₹159.14 crore. Rising costs, including materials and employee benefits, impacted profitability. The company's equity share capital doubled due to a 1:1 bonus share issuance.
26Aug 25
Anuh Pharma Shareholders Approve Key Leadership Appointments and Auditor Reappointments at 65th AGM
Anuh Pharma Limited held its 65th Annual General Meeting on August 22, 2025. Shareholders approved reappointments of Non-Executive Directors Bharat Nemchand Shah and Gaurav Satish Shah, and Joint Managing Directors Ritesh Shah and Vivek Shah for a five-year term. Mr. Ankit Kishor Chande was reappointed as Cost Auditor, and M/s. GHV & Co. as Secretarial Auditor for five years. All resolutions received over 99.99% votes in favor. A dividend of Rs. 1.50 per equity share was declared for FY 2024-25.
08Aug 25
Anuh Pharma Reports Q1 Revenue Growth, Appoints New Chief Marketing Officer
Anuh Pharma Limited announced Q1 financial results with revenue from operations increasing by 35.2% year-over-year to Rs 18,647.94 lakhs. However, profit after tax decreased slightly to Rs 830.12 lakhs. The company's EBITDA margin declined to 7.34% from 10.36% in the previous year. Additionally, Anuh Pharma appointed Mr. Vinayak Shenoy as Chief Marketing Officer, effective August 11, 2025, bringing over 15 years of experience in APIs and Intermediates across global markets.
15Jul 25
Anuh Pharma Boosts Production Capacity with New Manufacturing Facility in Tarapur
Anuh Pharma Limited has inaugurated a new manufacturing facility, Manufacturing Block INT-1A, in Tarapur, Maharashtra. The facility, opened on July 15, 2025, will increase the company's production capacity by 200 MT/Annum, bringing the total to approximately 2,400 MT/Annum. The expansion includes an additional 40 KL of reactor capacity, enhancing the company's infrastructure to meet growing market demands in the pharmaceutical sector.
23May 25
Anuh Pharma Reports Mixed Q4 Results, Recommends Dividend
Anuh Pharma Ltd. released its Q4 FY2023-24 results, showing a 15.85% increase in revenue to ₹1,900 crore. However, net profit declined by 18.62% to ₹125 crore. The company's EBITDA margin contracted to 10.48%. Despite Q4 challenges, annual performance for FY2024 was strong with a 23.52% revenue growth and 66.02% increase in net profit. The board recommended a dividend of ₹1.50 per equity share.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,789.90
(-0.37%)
6,533.00
(-0.31%)
4,317.90
(-0.75%)
1,379.30
(-0.79%)
1,078.30
(-1.18%)
1,274.00
(-1.27%)
2,249.80
(-0.58%)
2,299.00
(-0.91%)
1,429.20
(-0.31%)
1,382.60
(-0.42%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
